Innovative healthcare drugs and therapies offer the potential to improve the lives of millions of people living with cancer in Europe, yet significant differences in time-to-access remain for most of the new therapeutic interventions. How to ensure effective innovations are accessible and affordable to all patients is a challenge facing all stakeholders in the field of cancer.
